Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives.

Abstract

Immune checkpoint inhibitors (ICIs), especially anti-programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies, have made dramatic progress in the treatment of lung cancer, especially for patients with cancers not driven by oncogenes. However, responses are limited to a subset of patients, and which subset of patients will optimally benefit from ICI remains unknown. With the advantage of being minimally invasive and dynamic, noninvasive biomarkers are promising candidates to predict response, monitor resistance, and track the evolution of lung cancer during ICI treatment. In this review, we focus on the application of circulating tumor DNA (ctDNA) in plasma in immunotherapy. We examine the potential of pre- and on-treatment features of ctDNA as biomarkers, and following multiparameter analysis, we determine the potential clinical value of integrating predictive liquid biomarkers of ICIs to optimize patient management. We further discuss the role of ctDNA in monitoring treatment resistance, as well as challenges in clinical translation.

• Authors: Chang Lu, Yi-Chen Zhang, Zhi-Hong Chen, Qing Zhou, Yi-Long Wu
• Journal: Frontiers in oncology (Front Oncol) Vol. 12 Pg. 836891 ( 2022) ISSN: 2234-943X [Print] Switzerland
• PMID: 35359372 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2022 Lu, Zhang, Chen, Zhou and Wu.